Showing 1,781 - 1,800 results of 13,395 for search '(( significant ((nn decrease) OR (point decrease)) ) OR ( significant increase decrease ))', query time: 0.47s Refine Results
  1. 1781
  2. 1782
  3. 1783
  4. 1784
  5. 1785
  6. 1786
  7. 1787
  8. 1788
  9. 1789
  10. 1790
  11. 1791
  12. 1792
  13. 1793
  14. 1794

    CHAMPS pilot Hb dataset. by Jeanie du Toit (20721918)

    Published 2025
    “…Postmortem testing showed a significant decrease in hemoglobin concentrations compared to antemortem levels. …”
  15. 1795
  16. 1796

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  17. 1797

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  18. 1798

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  19. 1799
  20. 1800